CTLA4 and neoplasm: B. pseudolongum administration combined with anti-CTLA-4 immunotherapy was found to induce Th1 differentiation and effector T cell function, which was supported by elevated IFN-γ production in splenic CD4+ and CD8+ T lymphocytes in tumor-free mice.